70 related articles for article (PubMed ID: 8819074)
1. In vitro and in vivo anti-leukemic efficacy of cyclic AMP modulating agents against human leukemic B-cell precursors.
Myers DE; Chandan-Langlie M; Chelstrom LM; Uckun FM
Leuk Lymphoma; 1996 Jul; 22(3-4):259-64. PubMed ID: 8819074
[TBL] [Abstract][Full Text] [Related]
2. Dual effect of cAMP on the writhing response in mice.
Brito GA; Saraiva SN; Falcão JL; Vale ML; Lima AA; Cunha FQ; Ribeiro RA
Eur J Pharmacol; 2001 Mar; 416(3):223-30. PubMed ID: 11290372
[TBL] [Abstract][Full Text] [Related]
3. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
4. Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia.
Perez DR; Smagley Y; Garcia M; Carter MB; Evangelisti A; Matlawska-Wasowska K; Winter SS; Sklar LA; Chigaev A
Oncotarget; 2016 Jun; 7(23):33960-82. PubMed ID: 27129155
[TBL] [Abstract][Full Text] [Related]
5. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
Myers DE; Uckun FM
Leuk Lymphoma; 1995 Jun; 18(1-2):119-22. PubMed ID: 8580813
[TBL] [Abstract][Full Text] [Related]
6. Effect of theophylline and aminophylline on transmitter release at the mammalian neuromuscular junction is not mediated by cAMP.
Nickels TJ; Schwartz AD; Blevins DE; Drummond JT; Reed GW; Wilson DF
Clin Exp Pharmacol Physiol; 2006; 33(5-6):465-70. PubMed ID: 16700879
[TBL] [Abstract][Full Text] [Related]
7. Cyclic AMP-induced p53 destabilization is independent of EPAC in pre-B acute lymphoblastic leukemia cells in vitro.
Safa M; Kazemi A; Zaker F; Razmkhah F
J Recept Signal Transduct Res; 2011 Jun; 31(3):256-63. PubMed ID: 21619452
[TBL] [Abstract][Full Text] [Related]
8. Suppression of growth and dissemination in human pre-B leukemia cells by tumor necrosis factor-alpha in scid mice.
Yoshida N; Ishii E; Mohri S; Nagumo F; Yoshidomi S; Miyazaki S
Leuk Lymphoma; 1999 Mar; 33(1-2):107-18. PubMed ID: 10194127
[TBL] [Abstract][Full Text] [Related]
9. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
Ek O; Gaynon P; Zeren T; Chelstrom LM; Myers DE; Uckun FM
Leuk Lymphoma; 1998 Sep; 31(1-2):143-9. PubMed ID: 9720724
[TBL] [Abstract][Full Text] [Related]
10. Effect of dibutyryl cyclic adenosine monophosphate on the gene expression of plasminogen activator inhibitor-1 and tissue factor in adipocytes.
Taniguchi M; Ono N; Hayashi A; Yakura Y; Takeya H
Thromb Res; 2011 Oct; 128(4):375-80. PubMed ID: 21496886
[TBL] [Abstract][Full Text] [Related]
11. Serotonin N-acetyltransferase (NAT) induction in mammalian retina: role of cyclic AMP and calcium ions.
Zurawska E; Nowak JZ
Folia Histochem Cytobiol; 1992; 30(1):5-11. PubMed ID: 1280231
[TBL] [Abstract][Full Text] [Related]
12. Prevention of tissue factor generation in mononuclear cells by agents known to increase intracellular cyclic AMP.
Tono-oka T; Nakayama M; Gotohda E; Takeda T
Tohoku J Exp Med; 1979 Feb; 127(2):161-7. PubMed ID: 216134
[TBL] [Abstract][Full Text] [Related]
13. Effect of exogenous cAMP and aminophylline on alveolar and lung liquid clearance in anesthetized sheep.
Berthiaume Y
J Appl Physiol (1985); 1991 Jun; 70(6):2490-7. PubMed ID: 1653207
[TBL] [Abstract][Full Text] [Related]
14. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
15. Good engraftment of B-cell precursor ALL in NOD-SCID mice.
Baersch G; Möllers T; Hötte A; Dockhorn-Dworniczak B; Rübe C; Ritter J; Jürgens H; Vormoor J
Klin Padiatr; 1997; 209(4):178-85. PubMed ID: 9293448
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of cell death in malignant vs normal B-cell precursors: implications for cAMP in development and treatment of BCP-ALL.
Naderi EH; Ugland HK; Diep PP; Josefsen D; Ruud E; Naderi S; Blomhoff HK
Blood; 2013 Mar; 121(10):1805-13. PubMed ID: 23299313
[TBL] [Abstract][Full Text] [Related]
17. Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation.
Shichijo M; Shimizu Y; Hiramatsu K; Inagaki N; Tagaki K; Nagai H
Int Arch Allergy Immunol; 1997 Dec; 114(4):348-53. PubMed ID: 9414138
[TBL] [Abstract][Full Text] [Related]
18. The opposite effects of cyclic AMP-protein kinase a signal transduction pathway on renal cortical and medullary Na+,K+-ATPase activity.
Bełtowski J; Marciniak A; Wójcicka G; Górny D
J Physiol Pharmacol; 2002 Jun; 53(2):211-31. PubMed ID: 12120897
[TBL] [Abstract][Full Text] [Related]
19. Effect of cAMP on inducible nitric oxide synthase gene expression: its dual and cell-specific functions.
Okado-Matsumoto A; Matsumoto A; Fujii J; Taniguchi N
Antioxid Redox Signal; 2000; 2(4):631-42. PubMed ID: 11213468
[TBL] [Abstract][Full Text] [Related]
20. Protamine-induced acute lung injury and the protective effect of agents that increase cAMP.
Hsu K; Wang D; Shen CY; Chiang CH
Proc Natl Sci Counc Repub China B; 1993 Apr; 17(2):57-61. PubMed ID: 7809275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
